Securities Times meldde dat CBD (cannabidiol, een niet-psychoactieve cannabinoïde), na jaren van ontwikkeling, geleidelijk een belangrijk groeipunt in de industrie is geworden te midden van de zwakte van e-sigaretten. Insiders uit de industrie zeiden dat fabrikanten van CBD-verstuivers goede zaken doen, ver boven het gemiddelde niveau van de industrie.

De handel in e-sigaretten was dit jaar zwak en de bestellingen zijn vergelijkbaar met de lijst. "Securities Times-verslaggever interviewde een leverancier van e-sigarettenbatterijen, de andere kant zei het. Het is duidelijk dat de recente Simol internationale aandelenkoers relatief zwak was, er is een reden waarom de industrie niet boomt. Simor aan de internationale gigant OEM, e-sigaretten die worden beïnvloed door de industriële omgeving zijn relatief groot. Wegwerp-e-sigaretten zijn de afgelopen jaren een brandpunt geweest voor de industrie en hebben geleidelijk e-sigaretten vervangen als de mainstream in het buitenland, maar na aanhoudende groei is er recentelijk een vertraging opgetreden.

The recent hot spot is cannabis CBD products," said Li Youqiang, an expert in the e-cigarette industry. After the year, the pattern of the e-cigarette industry has changed obviously. Some manufacturers are rising, while others are declining. He believes CBD products will continue to sell well, leading to some companies seizing the opportunity. CBD, also known as cannabidiol, is a compound naturally found in cannabis resin flowers. It is one of more than 100 "plant cannabinoids". Unlike THC, CBD does not cause the hallucinogenic effects of THC (tetrahydrocannabinol, a drug ingredient) and has no side effects of THC. In recent years, CBD has gradually been recognized by the public as low-concentration CBD appears in health care products, food and skin care products. CBD has analgesic properties and can also reduce anxiety, panic, and has fewer side effects associated with marijuana than many over-the-counter and prescription painkillers. The risk of dependence is also lower.

Due to the easterly trend of marijuana legalization, marijuana products have been promoted rapidly and recognized by consumers in recent years. Inhaling CBD vaping oil through atomizing equipment is one of the consumption methods. Its principle is similar to that of vaping, but because it does not contain nicotine, it does not need to accept strict supervision as tobacco products, and it does not need to pay high consumption tax, so manufacturers have greater freedom. This is a separation of the atomized product from the tobacco.

In the US market, CBD industry has also been suppressed by the policies of some state governments. Many enterprises are researching CBD alternative raw materials, and products centering on other rare components of industrial hemp such as CBG and CBN have begun to appear. These two components are not regulated by the US law at present.

The Brightfield Group's 2022 US CBD Mid-Year Report, released last July, FDA Impact and Path Forward, including projections for two scenarios, with and without Food and Drug Administration (FDA) regulation, in response to expectations and possible federal market change regulations if FDA guidance delays persist.

According to the Brightfield Group, the US industrial cannabis-derived CBD market is estimated to be worth about $5 billion in retail sales in 2022. If federal rules are implemented by 2024, sales are expected to reach $11 billion by 2027.

Brightfield Group is a leading research firm in emerging categories, including CBD, cannabis and health. Unique insight into the development of new markets by integrating multi-source data with AI and research expertise into cross-comparable data lakes.